Trials / Recruiting
RecruitingNCT07154342
A Study of IL4Rα Monoclonal Antibody in Patients With Seasonal Allergic Rhinitis
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Clinical Trial to Evaluate the Efficacy and Safety of GR1802 Injection in Combination With Background Therapy in Patients With SAR
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 150 (estimated)
- Sponsor
- Genrix (Shanghai) Biopharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Allergic rhinitis (AR) is a non-infectious chronic inflammatory disease of the nasal mucosa mainly mediated by immunoglobulin E after exposure to allergens in atopic individuals. The typical symptoms of AR are paroxysmal sneezing, watery rhinorrhea, itching, and nasal congestion, which may be accompanied by ocular symptoms, including eye itching, tearing, redness, and burning sensation, which are more common in patients with hay fever allergies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | GR1802 injection | Recombinant fully human anti-IL4Rα monoclonal antibody drug. |
| BIOLOGICAL | Placebo | Placebo |
Timeline
- Start date
- 2025-08-15
- Primary completion
- 2026-04-30
- Completion
- 2026-07-31
- First posted
- 2025-09-04
- Last updated
- 2025-09-04
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07154342. Inclusion in this directory is not an endorsement.